Jaguar Health Signs exclusive 5-year In-license Agreement
DENVER, Colo., Apr 16, 2024 (247marketnews.com)- Jaguar Health, Inc. (NASDAQ:JAGX) reported signing an exclusive 5-year in-license agreement with Venture Life Group PLC, an international consumer health company based in the United Kingdom, for Venture Life’s FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market.
“We are very happy to have executed the in-license agreement for Gelclair – and thus to have initiated Jaguar’s commercial footprint in our core focus area of cancer supportive care,” stated Lisa Conte, Jaguar’s president and CEO. “Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a protective gel with a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis. Unlike other products for oral mucositis, it is not a numbing agent and does not sting the mouth.”
Maged Ghaly, MD, a radiation oncologist at Northwell Health Cancer Institute, Monter Cancer Center, stated, “A key attribute in the management of head and neck cancer patients with Gelclair is, in my experience, to delay the onset which may decrease the severity of oral mucositis, allowing the patients to continue meeting their nutritional needs without having to go on a feeding tube, supporting their ability to withstand their 6 weeks of radiation therapy without having to go to lower doses or treatment interruptions, and to avoid the need for heavy prescription meds for oral mucositis-related pain.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com